Insider Selling: Insmed Incorporated (NASDAQ:INSM) COO Sells 42,975 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 42,975 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $78.61, for a total value of $3,378,264.75. Following the completion of the transaction, the chief operating officer now owns 146,082 shares of the company’s stock, valued at approximately $11,483,506.02. The trade was a 22.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Roger Adsett also recently made the following trade(s):

• On Thursday, February 6th, Roger Adsett sold 45,605 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $3,689,444.50.
• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The shares were sold at an average price of $68.72, for a total transaction of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Trading Down 1.2 %

INSM stock opened at $78.67 on Friday. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $82.04. The business’s 50-day moving average is $73.23 and its 200 day moving average is $73.20. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market cap of $14.07 billion, a price-to-earnings ratio of -14.17 and a beta of 1.11.

Analyst Ratings Changes

INSM has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Morgan Stanley boosted their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Stifel Nicolaus raised their price objective on shares of Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday. Truist Financial reaffirmed a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Insmed in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.60.

Institutional Trading of Insmed

Institutional investors have recently made changes to their positions in the company. Truist Financial Corp purchased a new position in Insmed in the 2nd quarter valued at $413,000. GAMMA Investing LLC raised its position in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares in the last quarter. Creative Planning boosted its position in Insmed by 31.2% during the third quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company’s stock worth $3,279,000 after acquiring an additional 10,668 shares during the last quarter. Finally, V Square Quantitative Management LLC purchased a new stake in Insmed during the 3rd quarter valued at about $30,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.